MPJE: Multistate Pharmacy Jurisprudence Examination Quiz: Adulterated Misbranded
20 questions · exam conditions
0:00
Adulterated MisbrandedQuestion 1 of 20

A pharmacist discovers several bottles of a prescription medication on the dispensing shelf that expired three months ago. A patient is waiting for a prescription to be filled. Which of the following best describes the regulatory status of the expired medication?

The medication is misbranded because its label displays an expiration date that is no longer accurate.
The medication is neither adulterated nor misbranded; expiration is a quality concern, not a regulatory classification.
The medication is adulterated because its strength, quality, or purity can no longer be guaranteed to meet the labeled specifications.
The medication is misbranded because it cannot be dispensed with adequate directions for use.
← Back to quizzes

MPJE: Multistate Pharmacy Jurisprudence Examination Quiz

MPJE: Multistate Pharmacy Jurisprudence Examination Quiz: Adulterated Misbranded

Practice Adulterated Misbranded in MPJE: Multistate Pharmacy Jurisprudence Examination with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Adulterated Misbranded, giving you a quick way to practice the rules, question types, and explanations that matter most for MPJE: Multistate Pharmacy Jurisprudence Examination.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A pharmacist discovers several bottles of a prescription medication on the dispensing shelf that expired three months ago. A patient is waiting for a prescription to be filled. Which of the following best describes the regulatory status of the expired medication?

  1. The medication is misbranded because its label displays an expiration date that is no longer accurate.
  2. The medication is neither adulterated nor misbranded; expiration is a quality concern, not a regulatory classification.
  3. The medication is adulterated because its strength, quality, or purity can no longer be guaranteed to meet the labeled specifications. (correct answer)
  4. The medication is misbranded because it cannot be dispensed with adequate directions for use.
Explanation: An expired drug product is adulterated under FDCA Section 501 because the manufacturer can no longer guarantee that it meets the strength, quality, and purity standards declared on the label. The drug may have degraded beyond acceptable limits. A is incorrect because the label does display the expiration date accurately; the issue is that the product is past it, which is an adulteration concern, not a labeling falsity. B is incorrect because expiration creates a definitive adulteration classification; it is not merely a quality concern outside the regulatory framework. D is incorrect because the directions for use are not the relevant misbranding provision here; adulteration is the correct classification.

Question 2

A pharmacy receives a shipment of an OTC analgesic product. Upon inspection, the pharmacist notices that the Drug Facts label is missing the required Warnings section entirely. Which of the following best describes the regulatory status of this product?

  1. The product is misbranded because OTC drug labeling must include required warnings, and their omission makes the labeling inadequate. (correct answer)
  2. The product is adulterated because the missing warning section indicates a manufacturing defect.
  3. The product is both adulterated and misbranded because labeling and manufacturing issues often occur together.
  4. The product is not misbranded because the warning information may be available from the manufacturer upon request.
Explanation: OTC drug products must include required labeling elements including warnings under FDA Drug Facts labeling regulations. A product whose label omits required warnings is misbranded under FDCA Section 502 because its labeling is inadequate and does not convey required safety information. A correctly identifies this as misbranding. B is incorrect because a labeling omission is a misbranding issue, not evidence of a manufacturing defect that would support adulteration. C is incorrect because a labeling deficiency alone does not cause adulteration; the two classifications address different types of violations. D is incorrect because off-label availability of information does not satisfy the requirement that the label itself contain the required information.

Question 3

A pharmacist receives a Class I recall notice for a lot of an antihypertensive medication she has recently dispensed to multiple patients. Which of the following best describes the pharmacist's obligations?

  1. The pharmacist should remove the remaining stock from the shelf but is not required to contact patients who already received the medication.
  2. The pharmacist must quarantine the remaining recalled stock, identify patients who received the recalled lot, and contact those patients as directed by the recall notice and applicable law. (correct answer)
  3. The pharmacist should wait for the manufacturer to contact affected patients directly before taking any action.
  4. The pharmacist's only obligation is to return the recalled product to the manufacturer; patient notification is the FDA's responsibility.
Explanation: A Class I recall indicates a reasonable probability of serious adverse health consequences or death. The pharmacist must immediately remove recalled stock from dispensing, identify patients who received the recalled lot, and notify those patients as directed by the recall notice and applicable law. A is incorrect because patient notification is a critical obligation during a Class I recall; failing to notify patients who received a potentially dangerous product is a significant compliance and patient safety failure. C is incorrect because waiting for the manufacturer is inappropriate given the serious risk; the pharmacist must act promptly and independently. D is incorrect because patient notification is also the pharmacy's responsibility and cannot be deferred entirely to the manufacturer or FDA.

Question 4

A patient returns a prescription medication claiming the tablets look different from what she has received before -- they are a different color and the imprint does not match prior fills of the same prescription. Which of the following is the most appropriate initial response?

  1. Reassure the patient that manufacturers occasionally change tablet appearance and no further action is needed.
  2. Quarantine the medication and investigate its authenticity before notifying relevant authorities if necessary. (correct answer)
  3. Return the product to the manufacturer and await their determination before taking any further steps.
  4. Contact the DEA immediately because counterfeit medications always involve controlled substance violations.
Explanation: A reported change in both tablet color and imprint that differs from prior lots of the same product is a potential indicator of a counterfeit or adulterated product. Under DSCSA and FDA product integrity requirements, the pharmacy should quarantine the returned product, investigate through trading partners to verify legitimacy, and if illegitimate, notify the FDA and trading partners. A is incorrect because while appearance changes do occasionally occur, an unexplained change in both color and imprint is a significant red flag that requires investigation, not reassurance. C is incorrect because returning the product without quarantine and investigation does not satisfy DSCSA obligations. D is incorrect because the FDA is the primary authority for counterfeit product reporting; the DEA is not involved unless controlled substances are specifically at issue.

Question 5

A pharmacy receives a Class II recall notice for a lot of a cholesterol medication, indicating that use may cause temporary adverse health consequences or that serious consequences are only remotely probable. Which of the following actions is required of the pharmacy?

  1. No action is required because Class II recalls only obligate the manufacturer.
  2. The pharmacy should monitor the situation but may continue dispensing until it receives a direct notice from the FDA.
  3. The pharmacy must remove the recalled lot from dispensing stock and follow the recall notice instructions, which may include patient notification depending on the nature of the defect. (correct answer)
  4. The pharmacy may substitute a therapeutically equivalent product and dispense it without disclosing the recall to the patient.
Explanation: All recall classes -- including Class II -- require pharmacies to act on recall notices. The pharmacy must remove affected stock from dispensing shelves and follow the specific instructions in the recall notice, which may include patient notification depending on the defect and potential health impact. A is incorrect because recalls apply throughout the supply chain including pharmacies; manufacturer-level action does not satisfy the pharmacy's independent obligations. B is incorrect because pharmacies may not continue dispensing recalled product while awaiting further direction; the notice triggers immediate action. D is incorrect because substituting a different product without disclosing the recall to the patient is not a transparent or legally appropriate response.

Question 6

A pharmacy receives a drug shipment and attempts to verify the product identifier through the DSCSA-required interoperable electronic tracing system, but verification fails -- the serialized product identifier does not return a valid result. Under current DSCSA requirements, which of the following is the most appropriate action?

  1. Accept the shipment because the physical product appears genuine and a system error is the most likely explanation for the failed verification.
  2. Quarantine the product, investigate with the trading partner, and notify the FDA if the product is confirmed illegitimate. (correct answer)
  3. Accept the shipment and resubmit the verification request within 30 days.
  4. Return the shipment immediately and report the distributor to the FDA for a DSCSA violation.
Explanation: Under DSCSA's enhanced drug tracing requirements, pharmacies must verify serialized product identifiers through the interoperable electronic tracing system. A failed verification -- where the serialized identifier does not return a valid result -- is a recognized trigger for suspect product status. The pharmacy must quarantine the product to prevent dispensing, investigate with the trading partner and manufacturer to attempt resolution, and if the product is confirmed illegitimate, notify the FDA and affected trading partners within the required timeframe. A is incorrect because a failed serialized identifier verification is a specific DSCSA red flag requiring investigation, not an assumption of a system error. C is incorrect because DSCSA does not provide a 30-day grace period to resubmit failed verifications while the product remains accessible; quarantine is required immediately upon identification of suspect status. D is incorrect because immediate return without investigation bypasses the required investigation step and is a disproportionate initial response.

Question 7

An FDA EUA for a vaccine is revoked after the public health emergency declaration ends. A pharmacy still has units of the EUA-authorized vaccine in its refrigerator. Which of the following best describes the pharmacy's obligations?

  1. The pharmacy may continue to administer the vaccine because patients who started the vaccine series have a right to complete it.
  2. The pharmacy may retain the product in inventory for future use if a similar emergency arises.
  3. The pharmacy may dispense remaining units to healthcare providers for clinical use because revocation only affects new shipments.
  4. Upon revocation, the product no longer has authorized status; the pharmacy must cease administration and follow FDA guidance on disposition of remaining product. (correct answer)
Explanation: When an EUA is revoked, the product's authorization ends and the pharmacy may not continue to administer or dispense it under the revoked EUA. The pharmacy must follow FDA guidance on appropriate disposition of remaining product, which may include return or destruction. A is incorrect because a revoked EUA does not create a carve-out for patients mid-series; the EUA is the legal basis for use and revocation ends that basis. B is incorrect because holding unauthorized product in inventory for speculative future use is not a recognized option under FDA law. C is incorrect because revocation applies to all remaining product in the supply chain, not only new shipments.

Question 8

A drug product is found to have both a label that omits a required dispensing warning and content uniformity test failures showing tablet potency varies by 25% within the same lot. Which of the following most accurately classifies this product?

  1. The product is adulterated only, because potency variation is the more serious violation.
  2. The product is both adulterated and misbranded; the potency variation constitutes adulteration under the compendial standard, and the missing required label warning constitutes misbranding. (correct answer)
  3. The product is misbranded only, because labeling deficiencies are the actionable regulatory violation in this scenario.
  4. A drug product cannot simultaneously be both adulterated and misbranded; only the more serious classification applies.
Explanation: A drug product can simultaneously be adulterated and misbranded, as these classifications address different compliance dimensions. Content uniformity failures causing 25% potency variation constitute adulteration under FDCA Section 501 by failing to meet compendial standards. A missing required label warning constitutes misbranding under FDCA Section 502. Both classifications apply independently to the same product. A is incorrect because severity does not determine whether misbranding also applies; both violations exist simultaneously. C is incorrect because adulteration applies independently of misbranding; the compendial standard failure is a distinct and parallel violation. D is incorrect as a matter of law; a drug product may simultaneously be both adulterated and misbranded under the FDCA.

Question 9

A pharmacy auditor discovers that a prescription medication requiring refrigeration at 2 to 8 degrees Celsius has been stored at room temperature for one month and dispensed to patients during that period. Which of the following most accurately analyzes the regulatory and compliance implications?

  1. The product is misbranded only, because the storage failure created a discrepancy between the label storage instructions and the actual conditions.
  2. No regulatory violation exists unless laboratory testing confirms that the product's strength actually degraded.
  3. The product is adulterated only if the manufacturer's storage deviation allowance was exceeded by more than 50%.
  4. The product is adulterated due to improper storage, requiring quarantine of remaining stock and evaluation for potential patient notification. (correct answer)
Explanation: Improper storage conditions that deviate from labeled requirements can compromise a drug's strength, quality, and purity, rendering it adulterated under FDCA Section 501. The pharmacy must quarantine remaining product, stop dispensing, assess the scope of distribution, and evaluate patient notification given the one-month dispensing history. A is incorrect because while failing to follow label instructions has a compliance dimension, the primary regulatory consequence of storage-induced degradation is adulteration, not misbranding. B is incorrect because FDCA adulteration does not require laboratory confirmation of actual degradation; conditions that may have compromised the product satisfy the statutory standard. C is incorrect because there is no 50% storage deviation threshold in the FDCA; any storage condition that may have compromised the product can trigger the adulteration classification.

Question 10

A batch of tablets is independently tested and found to contain 75% of the labeled active ingredient, well below the 90 to 100% range specified in the USP monograph. The tablets were manufactured by a licensed facility and all labeling elements are present and accurate. Which of the following most accurately classifies this product?

  1. The product is misbranded only, because the label's potency claim is now inaccurate.
  2. The product is adulterated due to failing to meet USP strength standards. (correct answer)
  3. The product is neither adulterated nor misbranded because the manufacturing facility is licensed and the label is otherwise present.
  4. The product is adulterated only if the strength deficiency was caused by intentional tampering.
Explanation: Under FDCA Section 501(e), a drug that purports to conform to an official compendium standard and whose strength falls below that standard is adulterated. At 75% of labeled potency, this product clearly falls below the USP standard. Additionally, the label's potency representation is now inaccurate, which may also support a misbranding classification. Adulteration is the primary and specific classification. A is incorrect because while the inaccurate potency claim could support misbranding, adulteration under Section 501(e) is the more direct and specific classification for a compendial strength deficiency. C is incorrect because facility licensing does not override a measurable deviation from compendial standards. D is incorrect because FDCA adulteration under Section 501(e) does not require intentional tampering; a strength deficiency alone is sufficient.

Question 11

A pharmacy receives a DSCSA suspect product notification from a trading partner regarding a lot of an anticoagulant. The pharmacy has already dispensed 12 units from this lot to patients over the past two weeks. Which of the following best describes the pharmacy's obligations?

  1. The pharmacy's only obligation is to quarantine the remaining stock; no patient notification is required because the product was dispensed before the suspect notification was received.
  2. The pharmacy must notify the FDA and trading partners immediately, but patient notification is solely the prescriber's responsibility.
  3. The pharmacy must quarantine remaining stock, investigate the suspect product claim with trading partners, notify the FDA if the product is confirmed illegitimate, and evaluate whether patient notification is warranted given the dispensing history and potential health risk. (correct answer)
  4. The pharmacy must recall all dispensed units from patients and return them to the distributor as part of the DSCSA investigation.
Explanation: DSCSA and patient safety obligations require the pharmacy to quarantine remaining stock, investigate with trading partners, and notify the FDA if the product is confirmed illegitimate. The prior dispensing of 12 units adds an obligation to evaluate patient notification and clinical follow-up based on the nature of the suspected issue and the health risk, particularly given that patients are on an anticoagulant. A is incorrect because prior dispensing does not eliminate patient notification obligations when a safety concern exists; it actually increases the urgency of the patient safety assessment. B is incorrect because pharmacies have independent DSCSA and patient safety obligations and cannot defer entirely to prescribers for patient notification. D is incorrect because requesting patients to return dispensed anticoagulants is not a standard DSCSA obligation and would be clinically inappropriate without prescriber coordination.

Question 12

A pharmacy receives a drug shipment and notices that several units have unusual discoloration and disturbed tamper-evident packaging. The pharmacy cannot determine whether the products are genuine. Under DSCSA requirements, which of the following best describes the appropriate immediate action?

  1. Dispense the products and report the suspected issue to the manufacturer after dispensing.
  2. Return the products to the distributor immediately without documentation.
  3. Quarantine the products and notify the FDA and trading partners if confirmed illegitimate. (correct answer)
  4. Notify the DEA because altered packaging likely indicates the presence of counterfeit controlled substances.
Explanation: Under DSCSA, when a pharmacy identifies a suspect product -- one that may be counterfeit, diverted, or otherwise unfit -- the pharmacy must immediately quarantine the product to prevent dispensing, conduct an investigation with trading partners, and if the product is confirmed illegitimate, notify the FDA and affected trading partners. A is incorrect because dispensing a suspect product before verification is a serious safety and regulatory violation. B is incorrect because returning products without documentation eliminates the chain-of-custody audit trail required by DSCSA. D is incorrect because the FDA -- not the DEA -- is the primary regulatory authority for DSCSA suspect product reporting.

Question 13

A hospital compounding pharmacist discovers after preparing a batch of sterile injectable preparations that the HEPA filter in the laminar airflow workbench used during compounding had failed its most recent certification test. Which of the following best describes the regulatory status of the preparations?

  1. The preparations are misbranded because the compounding records do not reflect the equipment failure.
  2. The preparations are not adulterated because the pharmacist used proper aseptic technique during preparation.
  3. Whether the preparations are adulterated cannot be determined without laboratory testing of each unit.
  4. The preparations are adulterated due to compounding under potentially unsafe conditions. (correct answer)
Explanation: Under FDCA Section 501(a)(2)(A), a drug is adulterated if it was prepared under insanitary conditions whereby it may have been contaminated or rendered injurious to health. A failed HEPA filter in a laminar airflow workbench used for sterile compounding creates a risk of microbial contamination that satisfies the insanitary conditions standard. Proof of actual contamination in individual units is not required. A is incorrect because the issue is adulteration from the compromised preparation environment, not misbranding from a recordkeeping gap. B is incorrect because aseptic technique alone cannot compensate for a compromised engineering control; the insanitary conditions themselves trigger adulteration. C is incorrect because FDCA does not require laboratory proof of contamination in each unit; the preparation conditions are sufficient to establish adulteration.

Question 14

A pharmacy is offered an opportunity to purchase a drug product imported from a foreign country at significantly below-market prices. The seller represents that the product meets the same specifications as the FDA-approved domestic version. Under the FDCA and DSCSA, which of the following best analyzes whether the pharmacy may purchase and dispense this product?

  1. The pharmacy may not purchase the product; FDCA prohibits unapproved imports and DSCSA requires traceable serialized identifiers not met by foreign products. (correct answer)
  2. The pharmacy may purchase the product if the foreign manufacturer holds an FDA drug establishment registration.
  3. The pharmacy may purchase the product because FDA-equivalent manufacturing standards in the foreign country make it legally equivalent to the domestic version.
  4. The pharmacy may purchase the product if it obtains a letter from the seller certifying the product's authenticity.
Explanation: FDCA Section 801 generally prohibits importation of prescription drugs not specifically approved for import. Additionally, DSCSA requires all prescription drug products in the U.S. supply chain to have a verifiable serialized product identifier traceable through the authorized domestic electronic tracing system. A foreign-sourced product offered outside legitimate supply chain channels cannot satisfy either requirement. A correctly identifies both legal barriers. B is incorrect because FDA establishment registration authorizes a facility to manufacture for the U.S. market through approved channels; it does not authorize pharmacies to purchase directly from foreign sources outside those channels. C is incorrect because equivalent manufacturing standards in another country do not substitute for FDA import approval or DSCSA chain-of-custody traceability requirements. D is incorrect because a seller's self-certification does not satisfy FDCA importation law or DSCSA product traceability requirements.

Question 15

A pharmacy's investigation with trading partners confirms that a drug product in its inventory is a counterfeit that was diverted from the legitimate supply chain. Under DSCSA, what is the distinction between a suspect product and an illegitimate product, and what obligations apply now that the product is confirmed illegitimate?

  1. Suspect and illegitimate products are interchangeable terms under DSCSA; the pharmacy must return both categories to the distributor.
  2. A suspect product requires quarantine; an illegitimate product may be dispensed if no suitable therapeutic alternative is available.
  3. A suspect product is unconfirmed; an illegitimate product is confirmed. Notify FDA and trading partners, and quarantine the illegitimate product. (correct answer)
  4. Upon confirmation that a product is illegitimate, the pharmacy must notify the DEA and state board of pharmacy within 24 hours.
Explanation: DSCSA distinguishes suspect products -- those potentially counterfeit, diverted, or otherwise unfit but not yet confirmed -- from illegitimate products, which are confirmed to be counterfeit, diverted, stolen, or intentionally adulterated. Upon confirmation of illegitimacy, the pharmacy must quarantine the product and notify the FDA and affected trading partners within 24 hours. A is incorrect because the two terms carry different evidentiary thresholds and trigger distinct response obligations. B is incorrect because a confirmed illegitimate product must never be dispensed under any circumstances. D is incorrect because DSCSA illegitimate product reporting goes to the FDA and trading partners, not to the DEA or state board.

Question 16

An OTC cough syrup product's label states it is effective for all respiratory illnesses including pneumonia and bronchitis. These claims are not supported by FDA-approved clinical evidence. Which of the following best describes the regulatory status of this product?

  1. The product is misbranded because its labeling contains false or misleading therapeutic claims. (correct answer)
  2. The product is adulterated because unsupported label claims indicate the presence of unapproved active ingredients.
  3. The product is neither adulterated nor misbranded; unsupported claims are regulated solely as advertising, not labeling.
  4. The product is misbranded only if a consumer is actually harmed by relying on the false claims.
Explanation: A drug product whose labeling contains false or misleading claims is misbranded under FDCA Section 502(a). Therapeutic claims not supported by substantial evidence of effectiveness and not included in an approved drug application constitute false and misleading labeling. A correctly identifies this as misbranding. B is incorrect because unsupported label claims do not indicate the presence of unapproved ingredients; misbranding is the correct framework. C is incorrect because for drug products, on-package claims are regulated as labeling under the FDCA, not merely as advertising. D is incorrect because misbranding does not require proof of actual consumer harm; the false or misleading nature of the labeling itself constitutes the violation.

Question 17

A pharmacist assigns a 30-day beyond-use date (BUD) to a compounded sterile preparation per USP 797 guidelines. A patient asks whether the BUD is the same as the manufacturer's expiration date. Which of the following is the most accurate response?

  1. The BUD and expiration date are legally identical; both indicate when the product becomes adulterated.
  2. The BUD is always more conservative than the manufacturer's expiration date.
  3. The BUD applies only to multi-dose vials; single-use vials use the manufacturer's expiration date.
  4. The BUD and expiration date differ; BUD is assigned by the compounder, not the manufacturer. (correct answer)
Explanation: The BUD and expiration date are distinct concepts. The manufacturer's expiration date is established through formal stability testing under GMP conditions. The BUD for a compounded preparation is assigned by the pharmacy based on applicable USP standards (795, 797, or 800) and reflects the limit after which the preparation should not be used. A is incorrect because while both involve product integrity, they are legally and scientifically distinct with different regulatory frameworks and derivation methods. B is incorrect because the BUD is not always more conservative; for some formulations it may be longer or shorter depending on the preparation type and USP guidelines applied. C is incorrect because the BUD versus expiration date distinction applies broadly to all compounded versus manufactured products, not based on vial type.

Question 18

An FDA inspection of a drug manufacturing facility finds significant GMP violations including pest infestation in the production area. Drugs produced at this facility would be classified as which of the following?

  1. Misbranded, because the label does not disclose the insanitary manufacturing conditions.
  2. Misbranded, because the packaging standards do not meet FDA requirements.
  3. Neither adulterated nor misbranded, absent evidence that individual drug lots were actually contaminated.
  4. Adulterated, due to insanitary conditions that could lead to contamination. (correct answer)
Explanation: FDCA Section 501(a)(2)(A) defines a drug as adulterated if it has been prepared, packed, or held under insanitary conditions whereby it may have been contaminated with filth or rendered injurious to health. Proof of actual contamination in individual lots is not required; the insanitary conditions themselves trigger the adulteration classification. A is incorrect because failure to disclose manufacturing conditions on the label is not the applicable misbranding category; adulteration applies directly. B is incorrect because packaging standards are not the issue here. C is incorrect because the statute does not require proof of lot-level contamination; the risk created by insanitary conditions is sufficient to establish adulteration.

Question 19

The FDA issues an Emergency Use Authorization (EUA) for an antiviral medication during a declared public health emergency. Which of the following correctly describes the labeling and documentation requirements for this EUA product?

  1. EUA products are exempt from all labeling requirements because the emergency nature of the authorization eliminates standard compliance obligations.
  2. EUA products must be dispensed with the same labeling as fully FDA-approved products.
  3. No documentation is required for EUA products because they are not subject to the same standards as approved drugs.
  4. EUA products require FDA-authorized fact sheets for healthcare providers and recipients, detailing EUA status, benefits, risks, and alternatives. (correct answer)
Explanation: FDA EUA authorizations require both a Fact Sheet for Healthcare Providers and a Fact Sheet for Recipients or Caregivers. These fact sheets serve as the authorized labeling for the EUA product and must include information on the EUA status, benefits, known and potential risks, FDA-approved alternatives, and in some cases the voluntary nature of use. A is incorrect because EUA does not eliminate labeling and documentation obligations; it substitutes EUA-specific materials for standard drug labeling. B is incorrect because EUA products use EUA-specific fact sheets rather than standard approved-drug package inserts. C is incorrect because documentation requirements are a core element of EUA compliance; records of dispensing or administration are required.

Question 20

A patient informs her pharmacist that she plans to purchase her prescription medication from a Canadian online pharmacy because it is significantly cheaper. Which of the following best describes the legal status of this importation?

  1. Importation of prescription drugs from Canada is generally prohibited, but FDA may not enforce against small personal-use quantities. (correct answer)
  2. Importation from Canada is fully legal because Canada has drug safety standards equivalent to those of the United States.
  3. Importation is legal for any FDA-approved drug regardless of the country of purchase.
  4. Importation is legal if the patient obtains a valid prescription from a Canadian physician.
Explanation: The FDCA generally prohibits the importation of prescription drugs by individuals from foreign countries, including Canada. The FDA has historically exercised enforcement discretion for small personal-use quantities but this is not a legal authorization; the practice remains technically prohibited. The pharmacist should advise the patient of the legal risk and safety concerns, including the inability to verify authenticity and quality of foreign-purchased products. B is incorrect because equivalent drug standards in another country do not make importation legal under U.S. law. C is incorrect because domestic FDA approval status does not authorize importation of that drug from a foreign source. D is incorrect because a Canadian prescription does not resolve U.S. importation law; the act of importation itself is the issue.